Abstract 4359746: Safety and Feasibility of Hyperkalemic Cardioplegia with Diazoxide in Cardiac Surgery: CPG-DZX Trial

Introduction: Adenosine triphosphate-sensitive potassium (K ATP ) channel opener diazoxide (DZX) is cardioprotective in multiple translational animal models. We report the first in human FDA approved Phase I safety and feasibility trial of diazoxide in hypothermic hyperkalemic cardioplegia in patients undergoing cardiac surgery. The aim of this study was to demonstrate the safety and feasibility of DZX in patients undergoing cardiac surgery. The results will support a future Phase III randomized controlled trial to evaluate stunning in patients after cardiac surgery with DZX. Hypothesis: We hypothesize that DZX can be safely administered in hypothermic hyperkalemic cardioplegia in cardiac surgery. Methods: Patients undergoing non-emergent cardiac surgery (coronary artery bypass, aortic, or valve) received 100 microM/L intracoronary DZX delivered in the first dose of hypothermic, hyperkalemic cardioplegia at the time of cross-clamp placement. Patients on K ATP channel inhibitors or with left ventricular ejection fraction (LVEF) <30% were excluded. Primary safety endpoints were changes in blood glucose, mean arterial pressure (MAP), and weight gain. Additional data collected included the presence of myocardial stunning (using a novel definition of the need for mechanical and/or inotropic support >24 and <72 hours), the difference in pre- and postoperative LVEF, and time to wean from bypass. Results: Thirty patients received intracoronary DZX. One serious adverse event occurred, unrelated to DZX. The mean MAPs before DZX were 59.8 mmHg (last intraoperative MAP before DZX) and 62.0 mmHg (lowest MAP within 5 min after DZX). Intraoperative glucose before DZX was a mean of 113 mg/dL (at case start) and a mean of 159 mg/dL after DZX (point-of-care, intraoperative). Patients gained a mean of 7.9 kg postoperatively (preoperative weight compared to 48-hr postoperative) (Table 1). In the first 12 hrs postoperatively, mean peak lactate was 5.6±5.1 and peak troponin was 12,531±18,615 ng/L. Two patients (6.7%) had stunning. Intraoperative transesophageal echocardiography (TEE) pre- and post-bypass showed that mean LVEF significantly increased from baseline (2.1±4.9%, p=0.024). Mean time to cardiac arrest was 80±44 seconds, and time to wean from bypass was 5±3 min (Table 2). Conclusion: Intracoronary DZX can be safely administered in hypothermic hyperkalemic cardioplegia in cardiac surgery.